Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and maintains $105 price target.
Barrington Research Maintains Outperform on Haemonetics, Maintains $105 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.